Everence Capital Management Inc. Takes $400,000 Position in Organon & Co. (NYSE:OGN)

Everence Capital Management Inc. bought a new stake in Organon & Co. (NYSE:OGN) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 27,720 shares of the company’s stock, valued at approximately $400,000.

Several other large investors also recently made changes to their positions in the company. Fairfield Bush & CO. lifted its position in Organon & Co. by 3.0% in the 1st quarter. Fairfield Bush & CO. now owns 16,302 shares of the company’s stock valued at $569,000 after acquiring an additional 481 shares in the last quarter. Natixis Advisors L.P. lifted its position in Organon & Co. by 52.5% in the 1st quarter. Natixis Advisors L.P. now owns 50,428 shares of the company’s stock valued at $1,761,000 after acquiring an additional 17,370 shares in the last quarter. MetLife Investment Management LLC lifted its position in Organon & Co. by 23.2% in the 1st quarter. MetLife Investment Management LLC now owns 68,987 shares of the company’s stock valued at $2,410,000 after acquiring an additional 12,969 shares in the last quarter. Panagora Asset Management Inc. lifted its position in Organon & Co. by 95.6% in the 1st quarter. Panagora Asset Management Inc. now owns 39,595 shares of the company’s stock valued at $1,383,000 after acquiring an additional 19,352 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in Organon & Co. by 6.6% in the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 33,926 shares of the company’s stock valued at $1,185,000 after acquiring an additional 2,101 shares in the last quarter. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Organon & Co.

In other Organon & Co. news, insider Kirke Weaver bought 2,720 shares of the stock in a transaction dated Thursday, February 22nd. The shares were bought at an average cost of $18.36 per share, for a total transaction of $49,939.20. Following the purchase, the insider now directly owns 15,181 shares of the company’s stock, valued at approximately $278,723.16. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 1.17% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, The Goldman Sachs Group raised their price target on shares of Organon & Co. from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Tuesday, February 20th.

Organon & Co. Price Performance

Shares of Organon & Co. stock opened at $17.86 on Friday. The firm has a market cap of $4.57 billion, a PE ratio of 4.47, a P/E/G ratio of 0.85 and a beta of 0.83. Organon & Co. has a 1 year low of $10.84 and a 1 year high of $24.79. The stock has a fifty day moving average price of $18.00 and a 200-day moving average price of $15.62.

Organon & Co. (NYSE:OGN) last released its earnings results on Thursday, February 15th. The company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.14. The company had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.55 billion. Organon & Co. had a negative return on equity of 212.00% and a net margin of 16.33%. As a group, equities analysts anticipate that Organon & Co. will post 4.08 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 14th. Stockholders of record on Monday, February 26th were paid a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a dividend yield of 6.27%. The ex-dividend date was Friday, February 23rd. Organon & Co.’s payout ratio is 28.00%.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.